In a recent study published in the Journal of Virology, researchers developed a recombinant bivalent vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza viruses.
JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a ...
Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Proteinase K - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company ...
Stay up to date on the latest science with Brush Up Summaries. Finally, although transgenic animals and mammalian cell culture systems promote optimal expression due to correct protein modifications, ...
Ensuring the safety of medical products, such as drugs, biologics, or devices, requires careful testing for contaminants. Bacterial endotoxins are a major concern for pharmaceutical manufacturers ...
Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic ...
Antibodies are among the most important protein-detecting reagents in research, yet they can be surprisingly unreliable. It’s an issue close to Alejandra Solache’s heart. “The way many antibodies are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results